Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: Several therapies have demonstrated efficacy for the treatment of active, moderate-to-severe Crohn disease and ulcerative colitis. These include agents which induce remission [ infliximab, certolizumaband adalimumab (CD only)] or maintain remission and spare corticosteroids [ infliximab,certolizumab and adalimumab (CD only)]. In the patient with UC there is evidence about the efficacy of Infliximab for induce remission in moderate to-severe cases. We present additional information about new drugs in development for the treatment of both diseases. CONCLUSION: There are evidence about the efficacy and safety of biologic therapies that maximize remission and minimize corticosteroid dependence in patients with moderate-to-severe CD and UC.
|
Authors | F J Bosques-Padilla, S L Galindo-Marines, J K Yamamoto-Farusho |
Journal | Revista de gastroenterologia de Mexico
(Rev Gastroenterol Mex)
Vol. 73
Issue 4
Pg. 217-30
( 2008)
ISSN: 0375-0906 [Print] Mexico |
Vernacular Title | Conceptos actuales acercadel tratamiento de la enfermedad inflamatoriaintestinal mediante terapia biológica. |
PMID | 19666271
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Cell Adhesion Molecules
- Steroids
- Interferons
- Curcumin
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Biological Therapy
(methods)
- Cell Adhesion Molecules
(antagonists & inhibitors)
- Colitis, Ulcerative
(therapy)
- Crohn Disease
(therapy)
- Curcumin
(therapeutic use)
- Humans
- Immunity, Innate
(physiology)
- Inflammatory Bowel Diseases
(therapy)
- Interferons
(therapeutic use)
- Steroids
(adverse effects, therapeutic use)
|